Cardiac macrophage subsets differentially regulate lymphatic network remodeling during pressure overload

Mathilde Bizou1,2, Romain Itier1,3,2, Mina Majdoubi1,2

  • 1I2MC, Toulouse University, Inserm, Université Paul Sabatier, Toulouse, France.

Scientific Reports
|August 20, 2021
PubMed

Insights

Cardiac macrophages play a key role in heart failure progression. Specific macrophage subsets regulate lymphatic vessel remodeling, impacting heart function during pathological hypertrophy.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Lymphatic System Research

Background:

  • The cardiac lymphatic network regulates interstitial fluid and immune cell movement.
  • Heart hypertrophy and failure lead to cardiac lymphatic remodeling and reduced efficiency.

Purpose of the Study:

  • To investigate the role of cardiac macrophage subpopulations in regulating cardiac lymphatic remodeling during pressure overload.
  • To identify specific macrophage markers and functions involved in pathological cardiac hypertrophy.

Main Methods:

  • Induction of heart hypertrophy and failure via transverse aortic constriction in mice.
  • Analysis of cardiac lymphatic vessels and macrophage populations (LYVE-1 positive/negative).
  • Assessment of lymphangiogenesis and gene expression (MMP12, CCR2).
  • Treatment with a CCR2 antagonist to evaluate its effect on macrophage subsets and lymphatic remodeling.

Main Results:

  • Cardiac lymphatic remodeling and reduced efficiency were observed during heart failure.
  • A subset of LYVE-1 positive cardiac macrophages promoted lymphangiogenesis.
  • LYVE-1 negative macrophages expressed MMP12, contributing to lymphatic remodeling.
  • CCR2 antagonist treatment preserved the lymphatic network by altering macrophage proportions.

Conclusions:

  • Distinct cardiac macrophage subpopulations have differential roles in regulating cardiac lymphatic function during pathological hypertrophy.
  • Macrophage-mediated lymphatic remodeling is a key mechanism in heart failure progression.
  • Targeting CCR2-mediated pathways may offer therapeutic strategies for heart failure.